How many stocks are there of Neovacs?
The current number of stocks of Neovacs is 351,680 undefined.
Neovacs Stocks 2025
Neovacs Stocks
351,680
Ticker
ALNEV.PA
ISIN
FR001400MV37
WKN
A1CVKR
In 2025, Neovacs had 351,680 outstanding stocks, a 3,171.44% change from the 10,750 stocks in the previous year.
The Neovacs Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2023 | 0.35 |
| 2022 | 0.01 |
| 2021 | 0.01 |
| 2020 | 0.01 |
| 2019 | 0.01 |
| 2018 | 0.01 |
| 2017 | 0.01 |
| 2016 | 0 |
| 2015 | 0 |
| 2014 | 23.46 |
| 2013 | 17.7 |
| 2012 | 16.57 |
| 2011 | 16.53 |
| 2010 | 16.63 |
| 2009 | 16.63 |
| 2008 | 16.63 |
| 2007 | 16.63 |
Neovacs shares outstanding FR001400MV37 · A1CVKR
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Neovacs earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Neovacs's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Neovacs’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neovacs's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2007 | 16.63 M Aktien |
| 2008 | 16.63 M Aktien |
| 2009 | 16.63 M Aktien |
| 2010 | 16.63 M Aktien |
| 2011 | 16.53 M Aktien |
| 2012 | 16.57 M Aktien |
| 2013 | 17.7 M Aktien |
| 2014 | 23.46 M Aktien |
| 2015 | 3,220 Aktien |
| 2016 | 4,410 Aktien |
| 2017 | 6,930 Aktien |
| 2018 | 10,750 Aktien |
| 2019 | 10,750 Aktien |
| 2020 | 10,750 Aktien |
| 2021 | 10,750 Aktien |
| 2022 | 10,750 Aktien |
| 2023 | 351,680 Aktien |
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Neovacs's Shares Outstanding
Neovacs's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Neovacs’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Neovacs’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Neovacs’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Neovacs stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Neovacs are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Neovacs evolved in recent years?
The number of shares of Neovacs has increased by 3,171.44% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Neovacs as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Neovacs?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 1/21/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/21/2025.
When did Neovacs pay the last dividend?
The last dividend was paid out on 1/21/2025.
What was the dividend of Neovacs in the year 2024?
In the year 2024, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
